Skip to main content
main-content
Erschienen in: Digestive Diseases and Sciences 7/2022

30.05.2022 | DDS CITATION CLASSICS

Discovery of the GI Effects of GLP-1: An Historical Perspective

verfasst von: Jens Juul Holst

Erschienen in: Digestive Diseases and Sciences | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

In 1993, my laboratory published an article in Digestive Diseases and Sciences that clearly demonstrated the pronounced effects of the newly discovered intestinal hormone, glucagon-like peptide-1 (GLP-1), on a number of gastrointestinal functions, including gastric emptying rate, gastric acid secretion, and pancreatic enzyme secretion. The gut hormone is released in response to nutrient intake, and in further experiments, its release from the ileum paralleled inhibition of both gastric and pancreatic secretions. Based on these studies, it was concluded that GLP-1 is an important regulator of the so-called ileal brake, a term given for the observation that ileal perfusion of lipids delayed gastric emptying, reduced food intake, and induced satiety Welch et al. (1985), in addition to its functions as an incretin hormone. GLP-1 was subsequently identified as a physiological inhibitor of appetite and food intake, and based on these actions, the GLP-1 receptor agonists are today considered among the most powerful and effective antiobesity and antidiabetic agents available, with the added benefits of reducing the risk of the cardiovascular and renal complications associated with these conditions.
Literatur
1.
Zurück zum Zitat Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993;38:665–673. PubMed Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993;38:665–673. PubMed
2.
Zurück zum Zitat Muller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130. PubMedPubMedCentral Muller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130. PubMedPubMedCentral
3.
Zurück zum Zitat Welch I, Saunders K, Read NW. Effect of ileal and intravenous infusions of fat emulsions on feeding and satiety in human volunteers. Gastroenterology. 1985;89:1293–1297. PubMed Welch I, Saunders K, Read NW. Effect of ileal and intravenous infusions of fat emulsions on feeding and satiety in human volunteers. Gastroenterology. 1985;89:1293–1297. PubMed
4.
Zurück zum Zitat Rehfeld JF, Heding LG, Holst JJ. Increased gut glucagon release as pathogenetic factor in reactive hypoglycaemia? Lancet. 1973;1:116–118. PubMed Rehfeld JF, Heding LG, Holst JJ. Increased gut glucagon release as pathogenetic factor in reactive hypoglycaemia? Lancet. 1973;1:116–118. PubMed
5.
Zurück zum Zitat Holst JJ. Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin–current status. Gastroenterology. 1983;84:1602–1613. PubMed Holst JJ. Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin–current status. Gastroenterology. 1983;84:1602–1613. PubMed
6.
7.
Zurück zum Zitat Thim L, Moody AJ. The primary structure of porcine glicentin (proglucagon). Regul Pept. 1981;2:139–150. PubMed Thim L, Moody AJ. The primary structure of porcine glicentin (proglucagon). Regul Pept. 1981;2:139–150. PubMed
8.
Zurück zum Zitat Holst JJ. Evidence that enteroglucagon (II) is identical with the C- terminal sequence (residues 33–69) of glicentin. Biochem J. 1982;207:381–388. PubMedPubMedCentral Holst JJ. Evidence that enteroglucagon (II) is identical with the C- terminal sequence (residues 33–69) of glicentin. Biochem J. 1982;207:381–388. PubMedPubMedCentral
9.
Zurück zum Zitat Bataille D, Tatemoto K, Gespach C, Jornvall H, Rosselin G, Mutt V. Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide. FEBS Lett. 1982;146:79–86. PubMed Bataille D, Tatemoto K, Gespach C, Jornvall H, Rosselin G, Mutt V. Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide. FEBS Lett. 1982;146:79–86. PubMed
10.
Zurück zum Zitat Sheikh SP, Baldissera FG, Karlsen FO, Holst JJ. Glicentin is present in the pig pancreas. FEBS Lett. 1985;179:1–6. PubMed Sheikh SP, Baldissera FG, Karlsen FO, Holst JJ. Glicentin is present in the pig pancreas. FEBS Lett. 1985;179:1–6. PubMed
11.
Zurück zum Zitat Moody AJ, Holst JJ, Thim L, Jensen SL. Relationship of glicentin to proglucagon and glucagon in the porcine pancreas. Nature. 1981;289:514–516. PubMed Moody AJ, Holst JJ, Thim L, Jensen SL. Relationship of glicentin to proglucagon and glucagon in the porcine pancreas. Nature. 1981;289:514–516. PubMed
12.
Zurück zum Zitat Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature. 1983;302:716–718. PubMed Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature. 1983;302:716–718. PubMed
13.
Zurück zum Zitat Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology. 1986;119:1467–1475. PubMed Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology. 1986;119:1467–1475. PubMed
14.
Zurück zum Zitat Holst JJ, Orskov C, Schwartz TW, Buhl T, Proglucagon Baldissera F. a potent insulinotropic hormone from the lower small intestine. Diabetologia 1986;29:78–107. Holst JJ, Orskov C, Schwartz TW, Buhl T, Proglucagon Baldissera F. a potent insulinotropic hormone from the lower small intestine. Diabetologia 1986;29:78–107.
15.
Zurück zum Zitat Holst JJ, Orskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 1987;211:169–174. PubMed Holst JJ, Orskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 1987;211:169–174. PubMed
16.
Zurück zum Zitat Buhl T, Thim L, Kofod H, Orskov C, Harling H, Holst JJ. Naturally occurring products of proglucagon 111–160 in the porcine and human small intestine. J Biol Chem. 1988;263:8621–8624. PubMed Buhl T, Thim L, Kofod H, Orskov C, Harling H, Holst JJ. Naturally occurring products of proglucagon 111–160 in the porcine and human small intestine. J Biol Chem. 1988;263:8621–8624. PubMed
17.
Zurück zum Zitat Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A. 1996;93:7911–7916. PubMedPubMedCentral Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A. 1996;93:7911–7916. PubMedPubMedCentral
18.
Zurück zum Zitat Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet. 1987;2:1300–1304. PubMed Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet. 1987;2:1300–1304. PubMed
19.
Zurück zum Zitat Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78–107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 1988;123:2009–2013. PubMed Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78–107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 1988;123:2009–2013. PubMed
20.
Zurück zum Zitat Loud FB, Chirstiansen J, Holst JJ, Petersen B, Kirkegaard P. Effect of endogenous pancreatic glucagon on gastric acid secretion in patients with duodenal ulcer before and after parietal cell vagotomy. Gut. 1981;22:359–362. PubMedPubMedCentral Loud FB, Chirstiansen J, Holst JJ, Petersen B, Kirkegaard P. Effect of endogenous pancreatic glucagon on gastric acid secretion in patients with duodenal ulcer before and after parietal cell vagotomy. Gut. 1981;22:359–362. PubMedPubMedCentral
21.
Zurück zum Zitat Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Oxyntomodulin from distal gut role in regulation of gastric and pancreatic functions. Dig Dis Sci 1989;34:1411–1419. PubMed Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Oxyntomodulin from distal gut role in regulation of gastric and pancreatic functions. Dig Dis Sci 1989;34:1411–1419. PubMed
22.
Zurück zum Zitat Schjoldager BT, Mortensen PE, Christiansen J, Orskov C, Holst JJ. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig Dis Sci. 1989;34:703–708. PubMed Schjoldager BT, Mortensen PE, Christiansen J, Orskov C, Holst JJ. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig Dis Sci. 1989;34:703–708. PubMed
23.
Zurück zum Zitat Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981–E988. PubMed Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981–E988. PubMed
24.
Zurück zum Zitat Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60:1561–1565. PubMedPubMedCentral Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60:1561–1565. PubMedPubMedCentral
25.
Zurück zum Zitat Layer P, Holst JJ, Grandt D, Goebell H. Ileal release of glucagon-like peptide-1 (GLP-1) association with inhibition of gastric acid secretion in humans. Dig Dis Sci 1995;40:1074–1082. PubMed Layer P, Holst JJ, Grandt D, Goebell H. Ileal release of glucagon-like peptide-1 (GLP-1) association with inhibition of gastric acid secretion in humans. Dig Dis Sci 1995;40:1074–1082. PubMed
26.
Zurück zum Zitat Groger G, Unger A, Holst JJ, Goebell H, Layer P. Ileal carbohydrates inhibit cholinergically stimulated exocrine pancreatic secretion in humans. Int J Pancreatol. 1997;22:23–29. PubMed Groger G, Unger A, Holst JJ, Goebell H, Layer P. Ileal carbohydrates inhibit cholinergically stimulated exocrine pancreatic secretion in humans. Int J Pancreatol. 1997;22:23–29. PubMed
27.
Zurück zum Zitat Holst JJ, Rasmussen TN, Harling H, Schmidt P. Effect of intestinal inhibitory peptides on vagally induced secretion from isolated perfused porcine pancreas. Pancreas. 1993;8:80–87. PubMed Holst JJ, Rasmussen TN, Harling H, Schmidt P. Effect of intestinal inhibitory peptides on vagally induced secretion from isolated perfused porcine pancreas. Pancreas. 1993;8:80–87. PubMed
28.
Zurück zum Zitat Wettergren A, Wojdemann M, Meisner S, Stadil F, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7–36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut. 1997;40:597–601. PubMedPubMedCentral Wettergren A, Wojdemann M, Meisner S, Stadil F, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7–36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut. 1997;40:597–601. PubMedPubMedCentral
29.
Zurück zum Zitat Wettergren A, Petersen H, Orskov C, Christiansen J, Sheikh SP, Holst JJ. Glucagon-like peptide-1 7–36 amide and peptide YY from the L- cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol. 1994;29:501–505. PubMed Wettergren A, Petersen H, Orskov C, Christiansen J, Sheikh SP, Holst JJ. Glucagon-like peptide-1 7–36 amide and peptide YY from the L- cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol. 1994;29:501–505. PubMed
30.
Zurück zum Zitat Wettergren A, Wojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol. 1998;275:G984–G992. PubMed Wettergren A, Wojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol. 1998;275:G984–G992. PubMed
31.
Zurück zum Zitat Brierley DI, de Lartigue G. Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating. Br J Pharmacol 2021;179:584. PubMed Brierley DI, de Lartigue G. Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating. Br J Pharmacol 2021;179:584. PubMed
32.
Zurück zum Zitat Holst JJ, Andersen DB, Grunddal KV. Actions of glucagon-like peptide-1 receptor ligands in the gut. Br J Pharmacol 2021;179:727. PubMed Holst JJ, Andersen DB, Grunddal KV. Actions of glucagon-like peptide-1 receptor ligands in the gut. Br J Pharmacol 2021;179:727. PubMed
33.
Zurück zum Zitat Geary N. Glucagon and the control of appetite. In: Lefebvre PJ, editor. Glucagon III. Handbook of Experimental Pharmacology 123. Berlin: Springer; 1996. p. 223–38. Geary N. Glucagon and the control of appetite. In: Lefebvre PJ, editor. Glucagon III. Handbook of Experimental Pharmacology 123. Berlin: Springer; 1996. p. 223–38.
34.
Zurück zum Zitat Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K et al. A role for glucagon-like peptide-1 in the central regulation of feeding [see comments]. Nature. 1996;379:69–72. PubMed Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K et al. A role for glucagon-like peptide-1 in the central regulation of feeding [see comments]. Nature. 1996;379:69–72. PubMed
35.
Zurück zum Zitat Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M et al. Central administration of GLP-1-(7–36) amide inhibits food and water intake in rats. Am J Physiol. 1996;271:R848–R856. PubMed Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M et al. Central administration of GLP-1-(7–36) amide inhibits food and water intake in rats. Am J Physiol. 1996;271:R848–R856. PubMed
36.
Zurück zum Zitat Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like Peptide 1 Promotes Satiety and Suppresses Energy Intake in Humans. J Clin Invest. 1998;101:515–520. PubMedPubMedCentral Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like Peptide 1 Promotes Satiety and Suppresses Energy Intake in Humans. J Clin Invest. 1998;101:515–520. PubMedPubMedCentral
37.
Zurück zum Zitat Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989. PubMed Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989. PubMed
38.
Zurück zum Zitat Carlsson LMS, Sjoholm K, Jacobson P, Andersson-Assarsson JC, Svensson PA, Taube M et al. Life Expectancy after Bariatric Surgery in the Swedish Obese Subjects Study. N Engl J Med. 2020;383:1535–1543. PubMedPubMedCentral Carlsson LMS, Sjoholm K, Jacobson P, Andersson-Assarsson JC, Svensson PA, Taube M et al. Life Expectancy after Bariatric Surgery in the Swedish Obese Subjects Study. N Engl J Med. 2020;383:1535–1543. PubMedPubMedCentral
39.
Zurück zum Zitat Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653–662. PubMed Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653–662. PubMed
40.
Zurück zum Zitat Sjostrom L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden A et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311:2297–2304. PubMed Sjostrom L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden A et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311:2297–2304. PubMed
41.
Zurück zum Zitat Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001;120:806–815. PubMed Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001;120:806–815. PubMed
42.
Zurück zum Zitat Jeppesen PB, Gabe SM, Seidner DL, Lee HM, Olivier C. Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure. Gastroenterology. 2018;154:874–885. PubMed Jeppesen PB, Gabe SM, Seidner DL, Lee HM, Olivier C. Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure. Gastroenterology. 2018;154:874–885. PubMed
43.
Zurück zum Zitat Kissow H. Glucagon-like peptides 1 and 2: intestinal hormones implicated in the pathophysiology of mucositis. Curr Opin Support Palliat Care. 2015;9:196–202. PubMed Kissow H. Glucagon-like peptides 1 and 2: intestinal hormones implicated in the pathophysiology of mucositis. Curr Opin Support Palliat Care. 2015;9:196–202. PubMed
44.
Zurück zum Zitat Yusta B, Baggio LL, Koehler J, Holland D, Cao X, Pinnell LJ et al. GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R. Diabetes. 2015;64:2537–2549. PubMed Yusta B, Baggio LL, Koehler J, Holland D, Cao X, Pinnell LJ et al. GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R. Diabetes. 2015;64:2537–2549. PubMed
Metadaten
Titel
Discovery of the GI Effects of GLP-1: An Historical Perspective
verfasst von
Jens Juul Holst
Publikationsdatum
30.05.2022
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 7/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-022-07519-3

Weitere Artikel der Ausgabe 7/2022

Digestive Diseases and Sciences 7/2022 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.